Medullary Thyroid Cancer

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

Selpercatinib extended PFS compared with two approved multikinase inhibitors for treatment of RET-mutant medullary thyroid cancer, according to the agent’s manufacturer.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.

Providers should consider clinical context, including comorbidities, when diagnosing and managing thyroid cancer in older adults, according to a study published in Thyroid.

The FDA granted accelerated approval to pralsetinib for treatment of certain patients with RET-altered thyroid cancer.

Selpercatinib appeared to be effective and safe for patients with RET-altered medullary thyroid cancer and RET fusion-positive non-small cell lung cancer, according to results of two studies published in The New England Journal of Medicine.

Vandetanib extended PFS among patients with symptomatic and progressive medullary thyroid cancer, according to results of a post hoc analysis of a randomized phase 3 study published in Journal of Clinical Oncology.

The FDA approved selpercatinib for the treatment of patients with one of three types of tumors that have RET alterations.